249 related articles for article (PubMed ID: 22992839)
21. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
22. Current concepts on cytomegalovirus infection after liver transplantation.
Lee SO; Razonable RR
World J Hepatol; 2010 Sep; 2(9):325-36. PubMed ID: 21161017
[TBL] [Abstract][Full Text] [Related]
23. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity.
Künzle N; Petignat C; Francioli P; Vogel G; Seydoux C; Corpataux JM; Sahli R; Meylan PR
Transpl Infect Dis; 2000 Sep; 2(3):118-26. PubMed ID: 11429022
[TBL] [Abstract][Full Text] [Related]
24. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
25. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
26. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Craig JC; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
[TBL] [Abstract][Full Text] [Related]
27. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus infections in solid organ transplantation: a review.
Ramanan P; Razonable RR
Infect Chemother; 2013 Sep; 45(3):260-71. PubMed ID: 24396627
[TBL] [Abstract][Full Text] [Related]
29. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation.
Ekenberg C; da Cunha-Bang C; Lodding IP; Sørensen SS; Sengeløv H; Perch M; Rasmussen A; Gustafsson F; Wareham NE; Kirkby N; Kjaer J; Helleberg M; Reekie J; Lundgren JD
Transpl Infect Dis; 2020 Apr; 22(2):e13252. PubMed ID: 31997565
[TBL] [Abstract][Full Text] [Related]
34. [Prevention of cytomegalovirus disease in lung transplantation].
Gavaldà J; Monforte V; Len Ó
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():46-51. PubMed ID: 22541923
[TBL] [Abstract][Full Text] [Related]
35. Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.
Lemonovich TL; Watkins RR
Curr Infect Dis Rep; 2012 Feb; 14(1):33-40. PubMed ID: 22125047
[TBL] [Abstract][Full Text] [Related]
36. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.
Girmenia C; Lazzarotto T; Bonifazi F; Patriarca F; Irrera G; Ciceri F; Aversa F; Citterio F; Cillo U; Cozzi E; Gringeri E; Baldanti F; Cavallo R; Clerici P; Barosi G; Grossi P
Clin Transplant; 2019 Oct; 33(10):e13666. PubMed ID: 31310687
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
38. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy.
Singh N
Rev Med Virol; 2006; 16(5):281-7. PubMed ID: 16878336
[TBL] [Abstract][Full Text] [Related]
39. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients.
Razonable RR
Infect Dis Clin North Am; 2013 Jun; 27(2):317-42. PubMed ID: 23714343
[TBL] [Abstract][Full Text] [Related]
40. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?
McGillicuddy JW; Weimert NA; Taber DJ; Turner A; Mitchell LA; Wray DW; Egidi MF; Kuppachi S; Hughes MG; Baliga PK; Chavin KD
Transplantation; 2010 May; 89(10):1218-23. PubMed ID: 20410854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
